Market Recap: Zentalis Pharmaceuticals Inc (ZNTL)’s Positive Momentum, Closing at 12.52

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $12.52 for the day, up 0.72% from the previous closing price of $12.43. In other words, the price has increased by $0.72 from its previous closing price. On the day, 0.59 million shares were traded. ZNTL stock price reached its highest trading level at $12.857 during the session, while it also had its lowest trading level at $12.22.


Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.19 and its Current Ratio is at 9.19. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on November 08, 2023, Downgraded its rating to Neutral and sets its target price to $12 from $38 previously.

On November 07, 2023, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $15.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 09 ’24 when HAUSMAN DIANA sold 3,356 shares for $12.62 per share. The transaction valued at 42,353 led to the insider holds 373,876 shares of the business.

Epperly Melissa B, sold 2,573 shares of ZNTL for $29,435 on Feb 12 ’24. The Chief Financial Officer now owns 451,449 shares after completing the transaction at $11.44 per share. On Feb 12 ’24, another insider, Gallagher Cam, who serves as the President of the company, sold 1,173 shares for $11.44 each. As a result, the insider received 13,419 and left with 643,277 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 889085312 and an Enterprise Value of 439065472. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.92 while its Price-to-Book (P/B) ratio in mrq is 1.94. Its current Enterprise Value per Revenue stands at 10.825 whereas that against EBITDA is -2.117.

Stock Price History:

The Beta on a monthly basis for ZNTL is 1.84, which has changed by -0.52411944 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $31.46, while it has fallen to a 52-week low of $9.56. The 50-Day Moving Average of the stock is -8.55%, while the 200-Day Moving Average is calculated to be -24.47%.

Shares Statistics:

ZNTL traded an average of 815.22K shares per day over the past three months and 678480 shares per day over the past ten days. A total of 70.77M shares are outstanding, with a floating share count of 63.84M. Insiders hold about 10.10% of the company’s shares, while institutions hold 109.83% stake in the company. Shares short for ZNTL as of 1713139200 were 16637859 with a Short Ratio of 20.41, compared to 1710460800 on 16735039. Therefore, it implies a Short% of Shares Outstanding of 16637859 and a Short% of Float of 31.89.

Earnings Estimates

Zentalis Pharmaceuticals Inc (ZNTL) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.86 for the current quarter, with a high estimate of -$0.47 and a low estimate of -$0.96, while EPS last year was -$1.85. The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.52 and low estimates of -$0.99.

Analysts are recommending an EPS of between -$1.42 and -$3.9 for the fiscal current year, implying an average EPS of -$2.84. EPS for the following year is -$3.71, with 10.0 analysts recommending between -$2.76 and -$4.05.

Most Popular

[the_ad id="945"]